The combination therapy may alter the immune cell populations within the tumor microenvironment with more effector CD8+ T cells, neoantigen‐specific CD8+ T cells, type 1 helper CD4+ T cells and proinflammatory macrophages, shifting the tumor microenvironment from immunosuppressive to immunoactive state.[2, 47, 64, 65, 66] In addition, the mice in different treatment groups experienced little body weight loss (Figure S15, Supporting Information) during the course of the treatment, indicating that the combination therapy posed little toxicity to the mice. This evidence concerns the gene CD8A and neoplasm.